Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with myeloproliferative neoplasms

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wang, Min ^a   He, Na ^a   Tian, Tian ^a   Liu, Lu ^a   Yu, Shuang ^a   Ma, Daoxin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; GENOMIC DNA; JAK2V617F PROTEIN; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; CD135 ANTIGEN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA METHYLTRANSFERASE; FLT3 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; NUCLEAR PROTEIN;

ADULT; ARTICLE; CHINESE; DNA EXTRACTION; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENETICS; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; NUCLEAR PROTEINS;

EID: 84901751270     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/485645     Document Type: Article

References (44)

1. Klco J. M., Vij R., Kreisel F. H., Hassan A., Frater J. L., Molecular pathology of myeloproliferative neoplasms. American Journal of Clinical Pathology 2010 133 4 602 615 2-s2.0-77950476613 10.1309/AJCPPPZ1WFVGNE4A
2. Martínez-Avilés L., Besses C., Álvarez-Larrán A., Torres E., Serrano S., Bellosillo B., TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Annals of Hematology 2012 91 4 533 541 2-s2.0-80052418940 10.1007/s00277-011-1330-0
3. Abdel-Wahab O., Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology 2011 18 2 117 123 2-s2.0-79952042287 10.1097/MOH. 0b013e328343998e
4. Tefferi A., Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010 24 6 1128 1138 2-s2.0-77954581139
5. Luthra R., Vega-Vazquez F., Chen W., Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia. American Journal of Clinical Pathology 2006 126 4 530 533 2-s2.0-33749364564 10.1309/JT5B-E2L1-FGG8-P8Y6 (Pubitemid 44498502)
6. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S., Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996 10 12 1911 1918 2-s2.0-0030451722 (Pubitemid 27019637)
7. Yoshimoto G., Miyamoto T., Jabbarzadeh-Tabrizi S., Iino T., Rocnik J. L., Kikushige Y., Mori Y., Shima T., Iwasaki H., Takenaka K., Nagafuji K., Mizuno S., Niiro H., Gilliland G. D., Akashi K., FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009 114 24 5034 5043 2-s2.0-73949096431 10.1182/blood-2008- 12-196055
8. Nakajima H., Shibata F., Kumagai H., Shimoda K., Kitamura T., Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3. International Journal of Hematology 2006 84 1 54 59 2-s2.0-33748652484 10.1532/IJH97.06016 (Pubitemid 44756777)
9. Daver N., Strati P., Jabbour E., FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology 2013 88 1 56 59
10. Li L., Piloto O., Nguyen H. B., Greenberg K., Takamiya K., Racke F., Huso D., Small D., Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood 2008 111 7 3849 3858 2-s2.0-43549123118 10.1182/blood-2007-08-109942
11. Bains A., Luthra R., Medeiros L. J., Zuo Z., FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. American Journal of Clinical Pathology 2011 135 1 62 69 2-s2.0-79251500335 10.1309/AJCPEI9XU8PYBCIO
12. Sportoletti P., Grisendi S., Majid S. M., Cheng K., Clohessy J. G., Viale A., Teruya-Feldstein J., Pandolfi P. P., Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008 111 7 3859 3862 2-s2.0-43549116415 10.1182/blood-2007-06-098251
13. Chou S. H., Ko B. S., Chiou J. S., A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PloS ONE 2012 7 11 e49769
14. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R., Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V., Saglio G., Mandelli F., Lo-Coco F., Pelicci P., Martelli M. F., Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The New England Journal of Medicine 2005 352 3 254 266 2-s2.0-19944427850 10.1056/NEJMoa041974 (Pubitemid 40110814)
15. Brecqueville M., Cervera N., Gelsi-Boyer V., Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer Journal 2011 1 5, article e18
16. Abdel-Wahab O., Fathi A. T., Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Advances in Hematology 2012 2012 12 2-s2.0-80053545678 10.1155/2012/469592 469592
17. Ley T. J., Ding L., Walter M. J., McLellan M. D., Lamprecht T., Larson D. E., Kandoth C., Payton J. E., Baty J., Welch J., Harris C. C., Lichti C. F., Townsend R. R., Fulton R. S., Dooling D. J., Koboldt D. C., Schmidt H., Zhang Q., Osborne J. R., Lin L., O'Laughlin M., McMichael J. F., Delehaunty K. D., McGrath S. D., Fulton L. A., Magrini V. J., Vickery T. L., Hundal J., Cook L. L., Conyers J. J., Swift G. W., Reed J. P., Alldredge P. A., Wylie T., Walker J., Kalicki J., Watson M. A., Heath S., Shannon W. D., Varghese N., Nagarajan R., Westervelt P., Tomasson M. H., Link D. C., Graubert T. A., DiPersio J. F., Mardis E. R., Wilson R. K., DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine 2010 363 25 2424 2433 2-s2.0-78649906060 10.1056/NEJMoa1005143
18. Vardiman J. W., Thiele J., Arber D. A., Brunning R. D., Borowitz M. J., Porwit A., Harris N. L., Le Beau M. M., Hellström-Lindberg E., Tefferi A., Bloomfield C. D., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009 114 5 937 951 2-s2.0-70349256226 10.1182/blood-2009-03- 209262
19. Randi M. L., Ruzzon E., Tezza F., Scapin M., Duner E., Scandellari R., Fabris F., JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging-Clinical and Experimental Research 2011 23 1 17 21 2-s2.0-79956299123
20. Zhou J., Ye Y., Zeng S., Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS ONE 2013 8 2 e57856
21. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., Borrelli G., Rambaldi A., Barbui T., Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007 109 6 2310 2313 2-s2.0-33947262701 10.1182/blood-2006-09-046342 (Pubitemid 46425868)
22. Xu B., Chen G., Luo X., Tang J., Detection of FLT3/ITD gene mutations in patients with hematologic malignancy and their clinical significance. The Chinese-German Journal of Clinical Oncology 2009 8 2 100 103
23. Grundler R., Miething C., Thiede C., Peschel C., Duyster J., FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005 105 12 4792 4799 2-s2.0-20444402664 10.1182/blood-2004-11-4430 (Pubitemid 40807305)
24. Kelly L. M., Liu Q., Kutok J. L., Williams I. R., Boulton C. L., Gilliland D. G., FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002 99 1 310 318 2-s2.0-0036093475 10.1182/blood.V99.1.310 (Pubitemid 34532998)
25. Lee B. H., Williams I. R., Anastasiadou E., Boulton C. L., Joseph S. W., Amaral S. M., Curley D. P., Duclos N., Huntly B. J. P., Fabbro D., Griffin J. D., Gilliland D. G., FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 2005 24 53 7882 7892 2-s2.0-28344449144 10.1038/sj.onc.1208933 (Pubitemid 41715194)
26. Li L., Bailey E., Greenblatt S., Huso D., Small D., Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood 2011 118 18 4935 4945 2-s2.0-80855133514 10.1182/blood-2011-01-328096
27. Pardanani A., Reeder T. L., Kimlinger T. K., Baek J. Y., Li C., Butterfield J. H., Tefferi A., Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leukemia Research 2003 27 8 739 742 2-s2.0-0038204191 10.1016/S0145-2126(02)00303-X (Pubitemid 36683263)
28. Williams L., Kelley H. H., Meng X., Prada A., Crisan D., FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience. Diagnostic Molecular Pathology 2013 22 3 156 160
29. Cheng K., Sportoletti P., Ito K., Clohessy J. G., Teruya-Feldstein J., Kutok J. L., Pandolfi P. P., The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood 2010 115 16 3341 3345 2-s2.0-77951443641 10.1182/blood-2009-03-208587
30. Bolli N., Payne E. M., Grabher C., Lee J., Johnston A. B., Falini B., Kanki J. P., Look A. T., Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood 2010 115 16 3329 3340 2-s2.0-77951474555 10.1182/blood-2009-02-207225
31. Zhang Y., Zhang M., Yang L., Xiao Z., NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leukemia Research 2007 31 1 109 111 2-s2.0-33751230811 10.1016/j.leukres.2006.03.013 (Pubitemid 44780965)
32. Oki Y., Jelinek J., Beran M., Verstovsek S., Kantarjian H. M., Issa J. J., Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006 91 8 1147 1148 2-s2.0-33747013787 (Pubitemid 44204790)
33. Rocquain J., Carbuccia N., Trouplin V., Raynaud S., Murati A., Nezri M., Tadrist Z., Olschwang S., Vey N., Birnbaum D., Gelsi-Boyer V., Mozziconacci M., Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010 10, article 401 2-s2.0-77955081371 10.1186/1471-2407-10-401
34. Ernst T., Chase A., Zoi K., Waghorn K., Hidalgo-Curtis C., Score J., Jones A., Grand F., Reiter A., Hochhaus A., Cross N. C. P., Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 2010 95 9 1473 1480 2-s2.0-77956864003 10.3324/haematol.2010.021808
35. Schnittger S., Bacher U., Haferlach C., Alpermann T., Dicker F., Sundermann J., Kern W., Haferlach T., Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Leukemia 2011 25 4 615 621 2-s2.0-79958244398
36. Welch J. S., Ley T. J., Link D. C., The origin and evolution of mutations in acute myeloid leukemia. Cell 2012 150 2 264 278
37. Walter M. J., Ding L., Shen D., Shao J., Grillot M., McLellan M., Fulton R., Schmidt H., Kalicki-Veizer J., O'Laughlin M., Kandoth C., Baty J., Westervelt P., Dipersio J. F., Mardis E. R., Wilson R. K., Ley T. J., Graubert T. A., Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011 25 7 1153 1158 2-s2.0-79960255863 10.1038/leu.2011.44
38. Stegelmann F., Bullinger L., Schlenk R. F., Paschka P., Griesshammer M., Blersch C., Kuhn S., Schauer S., Döhner H., Döhner K., DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011 25 7 1217 1219 2-s2.0-79960210747 10.1038/leu.2011.77
39. Abdel-Wahab O., Pardanani A., Rampal R., Lasho T. L., Levine R. L., Tefferi A., DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011 25 7 1219 1220 2-s2.0-79960248721 10.1038/leu.2011.82
40. Lin J., Yao D., Qian J., Chen Q., Qian W., Li Y., Yang J., Wang C., Chai H., Qian Z., Xiao G., Xu W., Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 2011 6 10 2-s2.0-80055118997 10.1371/journal.pone.0026906 e26906
41. Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., Cervera N., Gelsi-Boyer V., Arnoulet C., Gisserot O., Verrot D., Slama B., Vey N., Mozziconacci M., Birnbaum D., Murati A., Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer 2012 51 8 743 755 2-s2.0-84859378570 10.1002/gcc.21960
42. Tefferi A., Lasho T. L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., Pieri L., Finke C. M., Kilpivaara O., Wadleigh M., Mai M., McClure R. F., Gilliland D. G., Levine R. L., Pardanani A., Vannucchi A. M., IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010 24 7 1302 1309 2-s2.0-77954658823 10.1038/leu.2010.113
43. Gutiyama L. M., Coutinho D. F., Lipkin M. V., Zalcberg I. R., Myeloid neoplasias: what molecular analyses are telling us. ISRN Oncology 2012 2012 7 321246 10.5402/2012/321246
44. Hatzimichael E., Georgiou G., Benetatos L., Briasoulis E., Gene mutations and molecularly targeted therapies in acute myeloid leukemia. American Journal of Blood Research 2013 3 1 29 51